Phase 3
Completed N=229
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
Intermediate Uveitis · Posterior Uveitis
Source: ClinicalTrials.gov NCT00333814 ↗
Enrolled (actual)
229
Serious AEs
8.0%
Results posted
Apr 2011
Primary outcomePrimary: Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero — 35.5; 46.8; 11.8 Percentage of Patients
Summary
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero |
35.5; 46.8; 11.8 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years or older with a diagnosis of chronic intermediate uveitis in at least one eye
Exclusion Criteria
- Uncontrolled systemic disease
- Any active ocular infections
Data sourced from ClinicalTrials.gov (NCT00333814). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.